| Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease P Chatterjee, S Pedrini, E Stoops, K Goozee, VL Villemagne, PR Asih, ... Translational psychiatry 11 (1), 27, 2021 | 354 | 2021 |
| Plasma amyloid as prescreener for the earliest A lzheimer pathological changes IMW Verberk, RE Slot, SCJ Verfaillie, H Heijst, ND Prins, ... Annals of neurology 84 (5), 648-658, 2018 | 344 | 2018 |
| Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology IMW Verberk, E Thijssen, J Koelewijn, K Mauroo, J Vanbrabant, ... Alzheimer's research & therapy 12, 1-14, 2020 | 205 | 2020 |
| ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project JL Ebenau, T Timmers, LMP Wesselman, IMW Verberk, SCJ Verfaillie, ... Neurology 95 (1), e46-e58, 2020 | 181 | 2020 |
| Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study EL van der Ende, LH Meeter, JM Poos, JL Panman, LC Jiskoot, ... The Lancet Neurology 18 (12), 1103-1111, 2019 | 179 | 2019 |
| Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau S Janelidze, S Palmqvist, A Leuzy, E Stomrud, IMW Verberk, H Zetterberg, ... Alzheimer's & Dementia 18 (2), 283-293, 2022 | 159 | 2022 |
| Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort … IMW Verberk, MB Laarhuis, KA van den Bosch, JL Ebenau, ... The lancet Healthy longevity 2 (2), e87-e95, 2021 | 159 | 2021 |
| CSF or serum neurofilament light added to α‐synuclein panel discriminates Parkinson's from controls LP Oosterveld, IMW Verberk, NK Majbour, OM El‐Agnaf, HC Weinstein, ... Movement Disorders 35 (2), 288-295, 2020 | 85 | 2020 |
| Comparison of ELISA-and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis S De Meyer, JM Schaeverbeke, IMW Verberk, B Gille, M De Schaepdryver, ... Alzheimer's research & therapy 12, 1-16, 2020 | 78 | 2020 |
| Highly specific and ultrasensitive plasma test detects Abeta (1–42) and Abeta (1–40) in Alzheimer’s disease EH Thijssen, IMW Verberk, J Vanbrabant, A Koelewijn, H Heijst, ... Scientific reports 11 (1), 9736, 2021 | 71 | 2021 |
| Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project IMW Verberk, HMA Hendriksen, AC van Harten, LMP Wesselman, ... Neurobiology of aging 89, 99-107, 2020 | 54 | 2020 |
| Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline J Stockmann, IMW Verberk, N Timmesfeld, R Denz, B Budde, ... Alzheimer's Research & Therapy 12, 1-13, 2020 | 53 | 2020 |
| Serum neurofilament light correlates with CADASIL disease severity and survival G Gravesteijn, JW Rutten, IMW Verberk, S Böhringer, MK Liem, ... Annals of clinical and translational neurology 6 (1), 46-56, 2019 | 46 | 2019 |
| Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients C Bridel, IMW Verberk, JJA Heijst, J Killestein, CE Teunissen Multiple sclerosis and related disorders 47, 102666, 2021 | 31 | 2021 |
| Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis M Chatterjee, MJA Koel-Simmelink, IMW Verberk, J Killestein, H Vrenken, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 4 (4 …, 2018 | 29 | 2018 |
| Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy FC Loonstra, IMW Verberk, MT Wijburg, MP Wattjes, CE Teunissen, ... Annals of neurology 86 (2), 322-324, 2019 | 18 | 2019 |
| Genetic Frontotemporal dementia Initiative (GENFI). Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study EL Van der Ende, LH Meeter, JM Poos, JL Panman, LC Jiskoot, ... Lancet Neurol 18 (12), 1103-1111, 2019 | 16 | 2019 |
| Pre-analytical sample handling effects on blood cytokine levels: Quality control of a COVID-19 biobank IMW Verberk, EJ Nossent, HJ Bontkes, CE Teunissen Biomarkers in medicine 15 (12), 987-997, 2021 | 15 | 2021 |
| Plasma p-tau217: from ‘new kid’to most promising candidate for Alzheimer’s disease blood test CE Teunissen, EH Thijssen, IMW Verberk Brain 143 (11), 3170-3172, 2020 | 15 | 2020 |
| Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis IMW Verberk, M Koel-Simmelink, H Twaalfhoven, H Vrenken, C Korth, ... Multiple sclerosis and related disorders 50, 102840, 2021 | 14 | 2021 |
